Abstract
Small supernumerary marker chromosomes (sSMC) in human are present in 0.043% of newborn children. They can be defined as additional centric chromosome fragments smaller than chromosome 20. sSMC include cases with the i(18p)-, the i(12p)- (i.e. Pallister Killian-) or the inv dup(22)- (i.e. cat-eye-) syndrome. However, about 30% of the remaining sSMC are not yet correlated with clinical syndromes, mostly due to problems in comprehensive characterisation of the sSMC. Here we present an overview of the approaches for sSMC characterisation and suggest a strategy for a straightforward and comprehensive characterisation of the marker chromosomes in question.
Keywords: small supernumerary marker chromosome, esac, ring chromosome, fluorescence in situ hybridisation, classification of ssmc
Current Genomics
Title: Characterisation of Small Supernumerary Marker Chromosomes (sSMC) in Human
Volume: 5 Issue: 3
Author(s): Thomas Liehr, Kristin Mrasek, Anja Weise, Alma Kuechler, Ferdinand von Eggeling, Uwe Claussen and Heike Starke
Affiliation:
Keywords: small supernumerary marker chromosome, esac, ring chromosome, fluorescence in situ hybridisation, classification of ssmc
Abstract: Small supernumerary marker chromosomes (sSMC) in human are present in 0.043% of newborn children. They can be defined as additional centric chromosome fragments smaller than chromosome 20. sSMC include cases with the i(18p)-, the i(12p)- (i.e. Pallister Killian-) or the inv dup(22)- (i.e. cat-eye-) syndrome. However, about 30% of the remaining sSMC are not yet correlated with clinical syndromes, mostly due to problems in comprehensive characterisation of the sSMC. Here we present an overview of the approaches for sSMC characterisation and suggest a strategy for a straightforward and comprehensive characterisation of the marker chromosomes in question.
Export Options
About this article
Cite this article as:
Liehr Thomas, Mrasek Kristin, Weise Anja, Kuechler Alma, Eggeling von Ferdinand, Claussen Uwe and Starke Heike, Characterisation of Small Supernumerary Marker Chromosomes (sSMC) in Human, Current Genomics 2004; 5 (3) . https://dx.doi.org/10.2174/1389202043349354
DOI https://dx.doi.org/10.2174/1389202043349354 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biodistribution and Pharmacokinetics of I-131 Labelled 4- Iodophenylacetic Acid
Current Radiopharmaceuticals Promising Pharmacological, Molecular and Cellular Treatments of Autoimmune Hepatitis
Current Pharmaceutical Design Natural Endoperoxides as Drug Lead Compounds
Current Medicinal Chemistry Melatonin and Aromatase in Breast Cancer
Clinical Cancer Drugs Targeting Epigenetics through Histone Deacetylase Inhibitors in Acute Lymphoblastic Leukemia
Current Cancer Drug Targets Synthesis and Biological Applications of Triazole Derivatives – A Review
Mini-Reviews in Organic Chemistry Novel Marine-Derived Anti-Cancer Agents
Current Pharmaceutical Design Aberrant Expression of MicroRNAs in B-cell Lymphomas
MicroRNA Resveratrol in Cancer: Cellular and Mitochondrial Consequences of Proton Transport Inhibition
Current Pharmaceutical Design Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy Combinatorial Protein Biochemistry for Therapeutics and Proteomics
Current Pharmaceutical Biotechnology The Family is Growing: Old and New Members of the Family of Site- Specific Recombinases and Their Application to Genome Engineering
Current Pharmacogenomics Synthesis, DNA Binding Ability and Anticancer Activity of 2-heteroaryl Substituted Benzimidazoles Linked Pyrrolo[2,1-c][1,4]benzodiazepine Conjugates
Medicinal Chemistry Studies on Coumarins and Coumarin-Related Compounds to Determine their Therapeutic Role in the Treatment of Cancer
Current Pharmaceutical Design Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Evaluation of the in vitro Chemosensitivity and Correlation with Clinical Outcomes in Lung Cancer using the ATP-TCA
Anti-Cancer Agents in Medicinal Chemistry Human Sirtuins: An Overview of an Emerging Drug Target in Age-Related Diseases and Cancer
Current Drug Targets Stem Cell Transplantation and MBL Replacement Therapy
Current Stem Cell Research & Therapy Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Current Cancer Drug Targets Recombinant Immunotoxins for the Treatment of Chemoresistant Hematologic Malignancies
Current Pharmaceutical Design